Michael Cherny
Stock Analyst at Leerink Partners
(4.39)
# 371
Out of 5,112 analysts
110
Total ratings
61.9%
Success rate
14.95%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $176.15 | +19.22% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $810.56 | +4.87% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $199.10 | -6.58% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $26.16 | +7.03% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.27 | +136.22% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $22.25 | +3.37% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $560.21 | -41.09% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $34.77 | +15.04% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $77.79 | -3.59% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $43.49 | +106.94% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $161.44 | +73.44% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $77.02 | +9.06% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $222.52 | +11.45% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $178.70 | +42.70% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.28 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $340.58 | -19.26% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $252.03 | +3.16% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.74 | +191.97% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $8.88 | +113.96% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.14 | +138.10% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.58 | +1,934.88% | 2 | Jan 5, 2022 |
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $176.15
Upside: +19.22%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $810.56
Upside: +4.87%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $199.10
Upside: -6.58%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $26.16
Upside: +7.03%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.27
Upside: +136.22%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $22.25
Upside: +3.37%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $560.21
Upside: -41.09%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $34.77
Upside: +15.04%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $77.79
Upside: -3.59%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $43.49
Upside: +106.94%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $161.44
Upside: +73.44%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $77.02
Upside: +9.06%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $222.52
Upside: +11.45%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $178.70
Upside: +42.70%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.28
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $340.58
Upside: -19.26%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $252.03
Upside: +3.16%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.74
Upside: +191.97%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $8.88
Upside: +113.96%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.14
Upside: +138.10%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.58
Upside: +1,934.88%